Nick Jovanoski

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Economic burden of advanced non-small cell lung cancer (NSCLC): a systematic literature review.

Economic burden of advanced non-small cell lung cancer (NSCLC): a systematic literature review.

Journal: Journal of medical economics

Published: February 22, 2026

A Cost-effectiveness Analysis of Adjuvant Alectinib in Patients With Resectable ALK -positive Non-small Cell Lung Cancer in the United States.

A Cost-effectiveness Analysis of Adjuvant Alectinib in Patients With Resectable ALK -positive Non-small Cell Lung Cancer in the United States.

Journal: American journal of clinical oncology

Published: March 28, 2025

Cost-Effectiveness of Adjuvant Alectinib Versus Chemotherapy for Patients with Resectable, ALK-positive Non-small Cell Lung Cancer in Canada.

Cost-Effectiveness of Adjuvant Alectinib Versus Chemotherapy for Patients with Resectable, ALK-positive Non-small Cell Lung Cancer in Canada.

Journal: PharmacoEconomics

Published: March 20, 2025

The long-term avoided recurrences and recurrence-related cost of alectinib for postoperative adjuvant therapy in Chinese patients with early-stage ALK-positive non-small cell lung cancer.

The long-term avoided recurrences and recurrence-related cost of alectinib for postoperative adjuvant therapy in Chinese patients with early-stage ALK-positive non-small cell lung cancer.

Journal: Frontiers in public health

Published: February 06, 2025

A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer.

A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 03, 2025

Avoided recurrences and costs with adjuvant atezolizumab for patients with early non-small cell lung cancer in Europe.

Avoided recurrences and costs with adjuvant atezolizumab for patients with early non-small cell lung cancer in Europe.

Journal: Immunotherapy

Published: November 26, 2024

Impact of Adjuvant Atezolizumab on Recurrences Avoided and Treatment Cost Savings for Patients with Stage II-IIIA Non-Small Cell Lung Cancer in Canada.

Impact of Adjuvant Atezolizumab on Recurrences Avoided and Treatment Cost Savings for Patients with Stage II-IIIA Non-Small Cell Lung Cancer in Canada.

Journal: Current oncology (Toronto, Ont.)

Published: April 19, 2024

Systematic Literature Review to Identify Cost and Resource Use Data in Patients with Early-Stage Non-small Cell Lung Cancer (NSCLC).

Systematic Literature Review to Identify Cost and Resource Use Data in Patients with Early-Stage Non-small Cell Lung Cancer (NSCLC).

Journal: PharmacoEconomics

Published: June 11, 2023

Health State Utility Values in Early-Stage Non-small Cell Lung Cancer: A Systematic Literature Review.

Health State Utility Values in Early-Stage Non-small Cell Lung Cancer: A Systematic Literature Review.

Journal: PharmacoEconomics - open

Published: May 10, 2023

Cost-effectiveness of adjuvant atezolizumab for patients with stage II-IIIA PD-L1+ non-small-cell lung cancer.

Cost-effectiveness of adjuvant atezolizumab for patients with stage II-IIIA PD-L1+ non-small-cell lung cancer.

Journal: Immunotherapy

Published: April 06, 2023

Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence.

Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence.

Journal: Lung cancer management

Published: March 02, 2023

Cost-effectiveness analysis of adjuvant atezolizumab in stage II-IIIA non-small cell lung cancer expressing ≥50% PD-L1: A United Kingdom health care perspective.

Cost-effectiveness analysis of adjuvant atezolizumab in stage II-IIIA non-small cell lung cancer expressing ≥50% PD-L1: A United Kingdom health care perspective.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 14, 2022

Showing 1-12 of 15

Last Updated: 09/26/2026